Raymond James Upgrades VBI Vaccines (VBIV) to Strong Buy; 'This Might Be the Best COVID Vaccine'
Tweet Send to a Friend
Raymond James analyst Steven Seedhouse upgraded VBI Vaccines (NASDAQ: VBIV) from Outperform to Strong Buy with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
